Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care

Recently, serious infections related to the use of tofacitinib (TOF) for treatment of rheumatoid arthritis (RA) have raised considerable interest. This study aimed to compare the risk for serious infections in patients with RA upon receiving TOF versus biologic disease-modifying antirheumatic drugs...

Descripción completa

Detalles Bibliográficos
Autores principales: Riek, Myriam, Scherer, Almut, Möller, Burkhard, Ciurea, Adrian, von Mühlenen, Ines, Gabay, Cem, Kyburz, Diego, Brulhart, Laure, von Kempis, Johannes, Mueller, Ruediger B., Hasler, Paul, Strahm, Tanja, von Känel, Sabine, Zufferey, Pascal, Dudler, Jean, Finckh, Axel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10584888/
https://www.ncbi.nlm.nih.gov/pubmed/37853058
http://dx.doi.org/10.1038/s41598-023-44841-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10584888/
https://www.ncbi.nlm.nih.gov/pubmed/37853058
http://dx.doi.org/10.1038/s41598-023-44841-w

Ejemplares similares